Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	Free PDFs: Hepatology 2013 (574 pages) – Hepatitis C 2013 Amedeo Smart: the Smartphone Edition	Free Abstracts

Ovarian Neoplasms

Free Subscription Articles published in Oncogene Retrieve available abstracts of 35 articles: HTML format Text format

Single Articles

January 2013
1. DO TV , Xiao F, Bickel LE, Klein-Szanto AJ, et al
   Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion.
   Oncogene. 2013 Jan 21. doi: 10.1038/onc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. XIANG Y , Ma N, Wang D, Zhang Y, et al
   MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine.
   Oncogene. 2013 Jan 14. doi: 10.1038/onc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   November 2012
3. CHAPMAN-ROTHE N , Curry E, Zeller C, Liber D, et al
   Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.
   Oncogene. 2012 Nov 5. doi: 10.1038/onc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. KUDO K , Gavin E, Das S, Amable L, et al
   Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair.
   Oncogene. 2012;31:4718-24.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   October 2012
5. VAN JAARSVELD MT , Helleman J, Boersma AW, van Kuijk PF, et al
   miR-141 regulates KEAP1 and modulates cisplatin sensitivity in ovarian cancer cells.
   Oncogene. 2012 Oct 8. doi: 10.1038/onc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   September 2012
6. BARROILHET L , Yang J, Hasselblatt K, Paranal RM, et al
   C-terminal binding protein-2 regulates response of epithelial ovarian cancer cells to histone deacetylase inhibitors.
   Oncogene. 2012 Sep 3. doi: 10.1038/onc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   August 2012
7. HOGNAS G , Tuomi S, Veltel S, Mattila E, et al
   Cytokinesis failure due to derailed integrin traffic induces aneuploidy and oncogenic transformation in vitro and in vivo.
   Oncogene. 2012;31:3597-606.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   July 2012
8. CHAU WK , Ip CK, Mak AS, Lai HC, et al
   c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/beta-catenin-ATP-binding cassette G2 signaling.
   Oncogene. 2012 Jul 16. doi: 10.1038/onc.2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   June 2012
9. PICCIONE EC , Lieu TJ, Gentile CF, Williams TR, et al
   A novel epidermal growth factor receptor variant lacking multiple domains directly activates transcription and is overexpressed in tumors.
   Oncogene. 2012;31:2953-67.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   May 2012
10. SHER YP , Chang CM, Juo CG, Chen CT, et al
    Targeted endostatin-cytosine deaminase fusion gene therapy plus 5-fluorocytosine suppresses ovarian tumor growth.
    Oncogene. 2012 May 7. doi: 10.1038/onc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2012
11. CHENG JC , Chang HM, Leung PC
    Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells.
    Oncogene. 2012 Apr 16. doi: 10.1038/onc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2012
12. YIN G , Alvero AB, Craveiro V, Holmberg JC, et al
    Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential.
    Oncogene. 2012 Feb 20. doi: 10.1038/onc.2012.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2012
13. MURA M , Swain RK, Zhuang X, Vorschmitt H, et al
    Identification and angiogenic role of the novel tumor endothelial marker CLEC14A.
    Oncogene. 2012;31:293-305.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. JEONG KJ , Park SY, Cho KH, Sohn JS, et al
    The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion.
    Oncogene. 2012 Jan 16. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. ZELLER C , Dai W, Steele NL, Siddiq A, et al
    Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling.
    Oncogene. 2012 Jan 16. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2011
16. ALBERTI C , Pinciroli P, Valeri B, Ferri R, et al
    Ligand-dependent EGFR activation induces the co-expression of IL-6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer.
    Oncogene. 2011 Dec 12. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. RATNER ES , Keane FK, Lindner R, Tassi RA, et al
    A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer.
    Oncogene. 2011 Dec 5. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
18. CAO L , Shao M, Schilder J, Guise T, et al
    Tissue transglutaminase links TGF-beta, epithelial to mesenchymal transition and a stem cell phenotype in ovarian cancer.
    Oncogene. 2011 Oct 3. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
19. WANG Y , Sheng Q, Spillman MA, Behbakht K, et al
    Gab2 regulates the migratory behaviors and E-cadherin expression via activation of the PI3K pathway in ovarian cancer cells.
    Oncogene. 2011 Sep 26. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. ALI AY , Abedini MR, Tsang BK
    The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation.
    Oncogene. 2011 Sep 19. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. YUE P , Zhang X, Paladino D, Sengupta B, et al
    Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Oncogene. 2011 Sep 12. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
22. RICHARDS JS , Fan HY, Liu Z, Tsoi M, et al
    Either Kras activation or Pten loss similarly enhance the dominant-stable CTNNB1-induced genetic program to promote granulosa cell tumor development in the ovary and testis.
    Oncogene. 2011 Aug 22. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
23. ZHANG Y , Cheng Y, Ren X, Zhang L, et al
    NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response.
    Oncogene. 2011 Jul 11. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. CHAO A , Lin CY, Lee YS, Tsai CL, et al
    Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2.
    Oncogene. 2011 Jul 4. doi: 10.1038/onc.2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
25. LAU MT , Klausen C, Leung PC
    E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via beta-catenin-Egr1-mediated PTEN expression.
    Oncogene. 2011;30:2753-66.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. BADGWELL DB , Lu Z, Le K, Gao F, et al
    The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways.
    Oncogene. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
27. FU G , Peng C
    Nodal enhances the activity of FoxO3a and its synergistic interaction with Smads to regulate cyclin G2 transcription in ovarian cancer cells.
    Oncogene. 2011.
    PubMed     Text format     Related articles   
    
    
    
    April 2011
28. REIMER D , Hubalek M, Kiefel H, Riedle S, et al
    Regulation of transcription factor E2F3a and its clinical relevance in ovarian cancer.
    Oncogene. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
29. AL-BAHLANI S , Fraser M, Wong AY, Sayan BS, et al
    P73 regulates cisplatin-induced apoptosis in ovarian cancer cells via a calcium/calpain-dependent mechanism.
    Oncogene. 2011.
    PubMed     Text format     Related articles   
    
    
    
    
30. ZHAI Y , Iura A, Yeasmin S, Wiese AB, et al
    MSX2 is an oncogenic downstream target of activated WNT signaling in ovarian endometrioid adenocarcinoma.
    Oncogene. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. CHENG JC , Auersperg N, Leung PC
    Inhibition of p53 represses E-cadherin expression by increasing DNA methyltransferase-1 and promoter methylation in serous borderline ovarian tumor cells.
    Oncogene. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. KIM JH , Yoon S, Park M, Park HO, et al
    Differential apoptotic activities of wild-type FOXL2 and the adult-type granulosa cell tumor-associated mutant FOXL2 (C134W).
    Oncogene. 2011;30:1653-63.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
33. MULLANY LK , Fan HY, Liu Z, White LD, et al
    Molecular and functional characteristics of ovarian surface epithelial cells transformed by KrasG12D and loss of Pten in a mouse model in vivo.
    Oncogene. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
34. CHEN X , Zhang H, Aravindakshan JP, Gotlieb WH, et al
    Anti-proliferative and pro-apoptotic actions of a novel human and mouse ovarian tumor-associated gene OTAG-12: downregulation, alternative splicing and drug sensitization.
    Oncogene. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
35. CHENG JC , Auersperg N, Leung PC
    Inhibition of p53 induces invasion of serous borderline ovarian tumor cells by accentuating PI3K/Akt-mediated suppression of E-cadherin.
    Oncogene. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

This service is provided by AMEDEO through a media sponsorship by Boehringer Ingelheim.

All AMEDEO services are free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Amedeo is a Flying Publisher website.    Design: